p.142 抽出テキスト

Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 2004; 15: 1046-1051. PMID: 15034108 293. Kobayashi S, Oka M, Maesato K, et al. Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol 2008; 3: 1289-1295. PMID: 18562597 294. Ishioka K, Ohtake T, Moriya H, et al. High prevalence of peripheral arterial disease (PAD) in incident hemodialysis patients: screening by ankle-brachial index (ABI) and skin perfusion pressure (SPP) measurement. Ren Replace Ther 2018; 4: 27. 295. Okamoto K, Oka M, Maesato K, et al. Peripheral arterial occlusive disease is more prevalent in patients with hemodialysis: Comparison with the findings of multidetector-row computed tomography. Am J Kidney Dis 2006; 48: 269-276. PMID: 16860193 296. Azuma N, Kikuchi S, Okuda H, et al. Recent Progress of Bypass Surgery to the Dialysis-Dependent Patients with Critical Limb Ischemia. Ann Vasc Dis 2017; 10: 178-184. PMID: 29147171 297. Iida O, Nakamura M, Yamauchi Y, et al. OLIVE Investigators. Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv 2013; 6: 68-76. PMID: 23362307 298. Iida O, Soga Y, Kawasaki D, et al. Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. Eur J Vasc Endovasc Surg 2012; 44: 425-431. PMID: 22938944 299. Dawson DB, Telles-Garcia NA, Atkins JL, et al. End-stage renal disease patients undergoing angioplasty and bypass for critical limb ischemia have worse outcomes compared to non-ESRD patients: Systematic review and meta-analysis. Catheter Cardiovasc Interv 2021; 98: 297-307. PMID: 33825331 300. Kobayashi S, Moriya H, Aso K, et al. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int 2003; 63: 1881- 1887. PMID: 12675867 301. Moriyama K, Kato Y, Hasegawa D, et al. Involvement of ionic interactions in cytokine adsorption of polyethyleneimine-coated polyacrylonitrile and polymethyl methacrylate membranes in vitro. J Artif Organs 2020; 23: 240-246. PMID: 32394409 302. Hokimoto S, Sakamoto K, Akasaka T, et al. High mortality rate in hemodialysis patients who undergo invasive cardiovascular procedures related to peripheral artery disease: Community-based observational study in Kumamoto Prefecture. Circ J 2015; 79: 1269- 1276. PMID: 25787229 303. Shiraki T, Iida O, Takahara M, et al. Predictors of 2-Year Mortality and Risk Stratification After Surgical or Endovascular Revascularization of Infrainguinal Artery Disease in Hemodialysis Patients With Critical Limb Ischemia. J Endovasc Ther 2015; 22: 719-724. PMID: 26276552 304. Ishii H, Aoyama T, Takahashi H, et al. Serum albumin and C-reactive protein levels predict clinical outcome in hemodialysis patients undergoing endovascular therapy for peripheral artery disease. Atherosclerosis 2013; 227: 130-134. PMID: 23294924 305. De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021; 32: 1474-1483. PMID: 33753537 306. Kobayashi S. Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 2008; 12: 9-15. PMID: 18175056 307. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339. PMID: 8918275 308. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106. PMID: 8298418 309. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86. PMID: 11786451 310. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials. JAMA 2009; 301: 1909-1919. PMID: 19436018 311. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207. PMID: 11196645 312. Hiatt WR, Fowkes FG, Heizer G, et al. EUCLID Trial Steering

Committee and Investigators. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 2017; 376: 32-40. PMID: 27959717 313. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has benefi-

cial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-686. PMID: 9715861 314. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008; 47: 330-336. PMID: 18155871 315. Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413. PMID: 22443427 316. De Schryver EL, Algra A, Kappelle LJ, et al. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev 2012: CD001342. PMID: 22972051 317. Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351. PMID: 10665553 318. Anand S, Yusuf S, et al. Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227. PMID: 17634457 319. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study. J Vasc Surg 2002; 35: 413-421. PMID: 11877686 320. Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315. PMID: 17659197 321. Gómez-Molina M, Valdés M, Marín F. Oral anticoagulation in Japanese patients with atrial fibrillation – insight to the use of non-vitamin K antagonist oral anticoagulants. Circ J 2015; 79: 292-294. PMID: 25744746 322. Toyoda K, Yasaka M, Iwade K, et al. Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745. PMID: 18388341 323. Ducrocq G, Wallace JS, Baron G, et al. REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010; 31: 1257-1265. PMID: 20181681 324. Hylek EM. Apixaban for End-Stage Kidney Disease: More Questions for the Randomized Trials. Circulation 2018; 138: 1534-1536. PMID: 30354524 325. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017; 377: 431-441. PMID: 28693366 326. Connolly SJ, Crowther M, Eikelboom JW, et al. ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019; 380: 1326-1335. PMID: 30730782 327. Panos NG, Cook AM, John S, et al. Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation 2020; 141: 1681-1689. PMID: 32264698 328. Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377: 1319-1330. PMID: 28844192 329. Cairns JA, Eikelboom JW, Shestakovska O, et al. Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. J Am Coll Cardiol 2019; 73: 2769-2772. PMID: 31146821 330. Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229. PMID: 29132880 331. Anand SS, Caron F, Eikelboom JW, et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol 2018; 71: 2306-2315. PMID: 29540326 332. Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk

in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk Circulation 2019; 140: 240-261. PMID: 31116032